Loading...
Loading...
RFL| Name | Value |
|---|---|
| Revenues | 336.0K |
| Cost of Revenue | 187.0K |
| Gross Profit | 149.0K |
| Operating Expense | 3,449.0K |
| Operating I/L | -3,300.0K |
| Other Income/Expense | -61,592.0K |
| Interest Income | 502.0K |
| Pretax | -64,892.0K |
| Income Tax Expense | -2,599.0K |
| Net Income/Loss | -32,351.0K |
Rafael Holdings, Inc. operates in the pharmaceuticals and real estate sectors. The company leases commercial office space and a public garage while also focusing on the development and commercialization of therapies targeting metabolic differences between normal and cancer cells. Its lead drug candidate, CPI-613 (devimistat), is undergoing clinical trials for metastatic pancreatic cancer and r/r acute myeloid leukemia. The company generates revenue through leasing real estate assets and potentially through the future commercialization of its pharmaceutical products.
